My watch list  

39 Current news of GE Healthcare


You can refine your search further. Select from the filter options on the left to narrow down your results.

GE Healthcare expands European capabilities to support accelerated biomanufacturing

Rapid Response Production service for research, process development, and bioproduction launched


GE Healthcare’s Life Sciences business announced that its European manufacturing and distribution site for sterile liquids has expanded its capabilities to include production of large volumes of buffers, process liquids and cell culture media, and launched a rapid production service for prototype ...


GE Healthcare and Takeda Join Forces to Develop Therapeutic Drugs to Target Liver Diseases


GE Healthcare and Takeda Pharmaceutical Company announced that they have entered into an alliance agreement for research and development in the field of hepatic fibrosis, a key factor in the diagnosis and treatment of liver diseases. Liver disease has almost no visible symptoms, and its progress ...


VTT and GE Healthcare developing novel biomarkers to predict Alzheimer’s disease


Scientists from VTT Technical Research Centre of Finland in collaboration with the University of Eastern Finland have recently discovered a serum biochemical signature which predicts progression to Alzheimer’s disease months or even years before the first symptoms of the disease occur. The goal ...


GE Healthcare Life Sciences completes acquisition of Xcellerex, Inc.


GE Healthcare announced that it has completed the acquisition of Xcellerex, Inc., a supplier of manufacturing technologies for the fast-growing biopharmaceutical industry. The acquisition expands GE Healthcare’s offering of technologies and services for the manufacture of biopharmaceuticals such ...


GE Healthcare and BAC collaborate to launch new bioprocess affinity resin


GE Healthcare and BAC BV announced that, following a successful collaboration between the two companies, GE Healthcare Life Sciences has added a new affinity resin to its portfolio of technologies for the purification of antibody-based fragments. GE Healthcare’s new resin, LambdaFabSelect, is a ...


GE Healthcare to acquire Xcellerex Inc., broadening capabilities in growing biopharmaceutical manufacture segment

Addition of high growth company builds integrated, start-to-finish industry offering, focused on lowering costs, increasing productivity and reducing time to market


GE Healthcare, a unit of GE announced it has reached an agreement to acquire Xcellerex, Inc. a supplier of innovative manufacturing technologies for the fast-growing biopharmaceutical industry. The acquisition of Xcellerex will allow GE Healthcare to expand its offering of products and services ...


GE Healthcare to Invest $1 Billion in New Oncology Solutions

Expanding advanced cancer diagnostic and molecular imaging capabilities


GE Healthcare, the health business of General Electric, announced its plans to dedicate $1 billion of its total R&D budget over the next five years to expand its advanced cancer diagnostic and molecular imaging capabilities, as well as its world-class technologies for the manufacture of ...


Gyros and GE Healthcare Life Sciences expand Asian distribution relationship to China, Taiwan and Hong Kong


Gyros AB announced that GE Healthcare Life Sciences has become sole distributor for the company’s nanoliter-scale immunoassay platform in China, Taiwan and Hong Kong. The Gyros platform is used by major biopharmaceutical companies and their service providers to improve productivity and efficiency ...


GE Healthcare to acquire PAA Laboratories GmbH


GE Healthcare announced it has reached an agreement to acquire PAA Laboratories, a developer and supplier of cell culture media for biomedical research and the fast-growing biopharmaceutical and vaccine manufacturing industry. The acquisition of PAA Laboratories will allow GE Healthcare to ...


Photocure: Hexvix/Cysview demonstrates long term benefit

Results from 5.5 year follow up of recurrence of bladder cancer


Photocure announced the results from a 5.5 year follow up of recurrence in patients with Non Muscle Invasive Bladder Cancer( NMIBC) showing a long term benefit of the use of Hexvix compared to patients who received white light cystoscopy alone. After a follow-up up period up to 5.5 years, the ...


Page 1 From 4
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE